These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 1308461)

  • 1. The definition of refractoriness to platelet transfusions.
    Bishop JF; Matthews JP; Yuen K; McGrath K; Wolf MM; Szer J
    Transfus Med; 1992 Mar; 2(1):35-41. PubMed ID: 1308461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical perspectives of platelet transfusions: defining the optimal dose.
    Strauss RG
    J Clin Apher; 1995; 10(3):124-7. PubMed ID: 8582893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination
    Thuku NW; Shikuku K; Mbugua A
    Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.
    Benson K; Fields K; Hiemenz J; Zorsky P; Ballester O; Perkins J; Elfenbein G
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):102-9. PubMed ID: 8211211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A; Pavenski K
    Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement as an Immune Barrier in Platelet Transfusion Refractoriness.
    Meinke S; Karlström C; Höglund P
    Transfus Med Rev; 2019 Oct; 33(4):231-235. PubMed ID: 31679761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of variation in donor platelet function on transfusion outcome: a semirandomized controlled trial.
    Kelly AM; Garner SF; Foukaneli T; Godec TR; Herbert N; Kahan BC; Deary A; Bakrania L; Llewelyn C; Ouwehand WH; Williamson LM; Cardigan RA
    Blood; 2017 Jul; 130(2):214-220. PubMed ID: 28487294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
    Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
    Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet Transfusion Practices in the ICU: Data From a Large Transfusion Registry.
    Ning S; Barty R; Liu Y; Heddle NM; Rochwerg B; Arnold DM
    Chest; 2016 Sep; 150(3):516-23. PubMed ID: 27102183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet transfusion therapy.
    Aisner J
    Med Clin North Am; 1977 Sep; 61(5):1133-45. PubMed ID: 330975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience.
    Karlström C; Linjama T; Edgren G; Lauronen J; Wikman A; Höglund P
    Transfusion; 2019 Mar; 59(3):945-952. PubMed ID: 30575964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for platelet transfusions. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force.
    Murphy MF; Brozovic B; Murphy W; Ouwehand W; Waters AH
    Transfus Med; 1992 Dec; 2(4):311-8. PubMed ID: 1339584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic use of platelets in critically ill patients with thrombocytopaenia: A retrospective two-centre observational study.
    O'Bryan LJ; Bedford J; Redfern OC; Hatch RA; Young JD; Watkinson PJ
    J Crit Care; 2020 Jun; 57():157-167. PubMed ID: 32163751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions.
    Abraham AS; Chacko MP; Fouzia NA; Srivastava A; Daniel D
    Transfus Med; 2018 Oct; 28(5):392-397. PubMed ID: 29460307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet transfusions: the problem of refractoriness.
    Murphy MF; Waters AH
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L; Woodfield DG
    N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POLYMORPHISM OF COLLECTION, TRANSFUSION AND EFFECTIVENESS OF DONOR PLATELETS CONCENTRATES.
    Gubanova MN; Ayupova RF; Zhiburt EB
    Anesteziol Reanimatol; 2017 Jan; 62(1):77-79. PubMed ID: 29932588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thrombocyte transfusion: increase in platelets in relation to clinical and immunologic prerequisites].
    Panzer S; Maier F; Höcker P; Mayr WR; Hinterberger W
    Infusionsther Klin Ernahr; 1987 Apr; 14 Suppl 2():10-4. PubMed ID: 3298059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.